Kodiak Sciences Inc. (NASDAQ:KOD) Shares Purchased by Silverarc Capital Management LLC

Silverarc Capital Management LLC grew its holdings in shares of Kodiak Sciences Inc. (NASDAQ:KOD - Free Report) by 100.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,000,000 shares of the company's stock after purchasing an additional 500,000 shares during the period. Kodiak Sciences makes up about 2.2% of Silverarc Capital Management LLC's portfolio, making the stock its 15th biggest holding. Silverarc Capital Management LLC owned about 1.90% of Kodiak Sciences worth $9,950,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the business. PNC Financial Services Group Inc. lifted its holdings in shares of Kodiak Sciences by 1,501.5% during the fourth quarter. PNC Financial Services Group Inc. now owns 3,187 shares of the company's stock worth $32,000 after purchasing an additional 2,988 shares during the period. US Bancorp DE purchased a new stake in shares of Kodiak Sciences in the 4th quarter valued at $40,000. Headlands Technologies LLC acquired a new stake in shares of Kodiak Sciences in the fourth quarter worth $90,000. JPMorgan Chase & Co. raised its holdings in shares of Kodiak Sciences by 220.9% during the third quarter. JPMorgan Chase & Co. now owns 44,648 shares of the company's stock worth $117,000 after purchasing an additional 30,735 shares during the last quarter. Finally, Fox Run Management L.L.C. acquired a new position in Kodiak Sciences during the fourth quarter valued at $118,000. Institutional investors and hedge funds own 89.06% of the company's stock.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a "neutral" rating and set a $3.00 target price on shares of Kodiak Sciences in a report on Monday, March 31st.

Kodiak Sciences Stock Performance

Shares of Kodiak Sciences stock traded down $0.08 on Friday, hitting $4.11. The company's stock had a trading volume of 252,155 shares, compared to its average volume of 343,298. The company has a market capitalization of $216.79 million, a price-to-earnings ratio of -1.13 and a beta of 2.40. The firm has a fifty day moving average price of $3.27 and a 200-day moving average price of $5.42. Kodiak Sciences Inc. has a 1 year low of $1.92 and a 1 year high of $11.60.

Kodiak Sciences (NASDAQ:KOD - Get Free Report) last announced its earnings results on Thursday, March 27th. The company reported ($0.84) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.90) by $0.06. As a group, analysts forecast that Kodiak Sciences Inc. will post -3.45 EPS for the current year.

About Kodiak Sciences

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.